Molzym is Now Part of Gradian Diagnostics!
16 December 2019
We are very pleased to inform you that Molzym GmbH & Co. KG has joined Gradian Diagnostics. Being part of Gradian Diagnostics allows us to accelerate growth and develop new innovative solutions that help hospitals and labs with the challenges and opportunities they face today and in the future in routine microbial pathogen diagnostics and molecular microbiology research.
Our highly experienced team of researchers, technicians and diagnostic specialists in addition to our businesses and services will remain unchanged. Our customers, distributors and partners can continue to rely on our high quality solutions and our excellent support. The offices and production site will remain in Bremen, Germany.
Gradian Diagnostics is a holding company based in Miami, USA, working on expanding diagnostic solutions by acquiring assets and companies with validated products around the world. Please follow the link for the official press release.
Molzym - Sample to Microbe
Molzym was founded as a privately owned enterprise in Bremen, North-West Germany, in 2003. Ever since, Molzym has been committed to the development of innovative solutions to serve biological research and diagnosis of infectious diseases. Our developmental efforts are particularly focused on new processes enabling and facilitating the molecular diagnosis of infectious diseases caused by bacteria and fungi. Meanwhile, more than 50 high quality products are available for molecular microbial analysis by PCR-, hybridization- and NGS-based methods in 30 countries worldwide.
Molzym manufactures ultra-clean and highly active amplification reagents and kits for microbial nucleic acid extraction from a variety of specimens. In particular, reagents and consumables are supplied free of contaminating microbial DNA – guaranteed lot by lot. Our customers appreciate the ability of increasing the number of amplification cycles and thus lowering the limit of detection dramatically without false positive results arising from contaminating microbial DNA. Another core expertise is Molzym’s unique technology of the depletion of human DNA, a well-known factor negatively influencing sensitive PCR and microbiome analysis at low microbial loads.
MolYsis™ is Molzym’s proprietary technology of human DNA depletion allowing targeted isolation of microbial DNA from a variety of clinical samples, including whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other material. Ultra-pure, DNA-free PCR reagents and master mixes allow for the precise detection and monitoring of aetiologies of infectious diseases in humans and animal models. Complete assays for the broad-range amplification of selected regions of the 16S and 18S rRNA genes of bacteria and fungi are available for PCR analysis at 40 cycles. Basic and dye master mixes can be used with custom primers for PCR and Real-Time PCR analysis.
The latest development is a walk-away robotic system, SelectNA™plus, for the fully automated human DNA depletion and extraction of microbial DNA from clinical and other material. SelectNA™plus conveys utmost technical advances to the demands for contamination-free and low-hands-on processing of samples for highest detection sensitivity of pathogens.
Molzym offers a service for the decontamination of customized master mixes from microbial DNA for improved assay performance at increased amplification cycles. Molzym offers opportunities for collaborations that are directed to the development and manufacturing of individualized, pre-analytic and analytic adaptations, including automated DNA isolation. Molzym has developed a broad portfolio of patented technologies and reagents for pathogen-DNA enrichment, isolation and detection, including PCR and NGS applications.